Premium
Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin‐treated hypertensive hypercholesterolemic patients
Author(s) -
Cicero Arrigo F.G.,
Veronesi Maddalena,
Prandin Maria Grazia,
Di Gregori Valentina,
Ambrosioni Ettore,
Borghi Claudio
Publication year - 2009
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2009.00719.x
Subject(s) - statin , medicine , angiotensin ii receptor type 1 , blood pressure , hemodynamics , peripheral , blocking (statistics) , cardiology , pharmacology , atorvastatin , receptor , endocrinology , angiotensin ii , statistics , mathematics
Recent evidences suggest a relationship between angiotensin 1 (AT1) receptor gene expression and low density lipoprotein cholesterol (LDL‐C) plasma level. We enrolled 16 untreated hypertensive hypercholesterolemic patients (57.4 ± 7 years old) in a randomized, single‐blind, cross‐over design. All the patients were allocated to treatment with simvastatin 20 mg/day for 2 weeks, then randomly assigned to telmisartan (40–80 mg/day) or bisoprolol (5–10 mg/day). After 4 weeks the antihypertensive drugs have been withdrawn for a wash‐out period of 2 weeks when they were treated with simvastatin alone, then they have been allocated to the alternative antihypertensive treatment for four additional weeks. We measured: systolic (SBP) and diastolic BP (DBP), 24‐h mean BP (MBP), Baseline and post‐ischemia forearm blood flow (FBF) and vascular resistance (FVR), and Lipid profile. After 2 weeks of treatment with Simvastatin, baseline and post‐ischemic FBF increased (both P < 0.05), while baseline and post‐ischemic FVR decreased (both P < 0.05). Standing DBP and MBP were reduced more after treatment with telmisartan than with bisoprolol ( P < 0.05). Basal and post‐ischemic FBF were significantly increased ( P < 0.05 and P < 0.005, respectively) and basal and post‐ischemic FVR significantly decreased (both P < 0.005) only after treatment with telmisartan, as well as plasma triglycerides (TG) ( P < 0.05). From this preliminary study carried out on hypercholesterolemic hypertensive patients it appears that the association of telmisartan and simvastatin (but not of bisoprolol and simvastatin) could exert positive effects on a large quantity of vascular functionality parameters, just after a short treatment.